bit.bio is a synthetic biology company developing precision-programmed human cells for biomedical research, drug discovery and future cell therapies. Its technology reprogrammes induced pluripotent stem cells into consistent, defined and scalable human cell types, helping researchers create more predictive disease models and reduce reliance on animal testing. The company sells ioCells, including neuronal, glial, muscle and immune cell products, alongside disease models, CRISPR-ready cells, assay support and custom cell development. Operating in the life sciences and biotechnology industry, bit.bio serves academic, pharmaceutical and biotech customers seeking reliable human cell platforms for research, screening and therapeutic innovation.
